Table 1 Comparison of severe asthma pathway waiting times between patient cohorts.
From: Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK
Pathway stage | Historic patients (n = 37) | Current patients (n = 143) | Significance | Mean change |
|---|---|---|---|---|
Mean weeks (range) | Mean weeks (range) | p-value | % change in waiting time | |
Stage 1: Referral to first appointment in secondary care | 21.2 (1.0–74.3) | 8.5 (1.0–26.1) | p = 0.002 | 59% reduction |
Stage 2: First appointment secondary care to follow-up/diagnosis | 24.3 (6.0–67.7) | 13.3 (1.0–45.1) | p < 0.001 | 45% reduction |
Stage 3: Follow-up/diagnosis to MDT discussion | 17.9 (2.0–40.8) | 6.7 (1.0–23.3) | p = 0.004 | 63% reduction |
Stage 4: MDT discussion to biologics initiation | 15.9 (4.0–99.9) | 8.0 (3.0–16.9) | p = 0.063 | 49% reduction (not statistically significant) |
Overall: Pathway from referral to treatment initiation | 76.4 (23.0–134.0) | 26.7 (16.0–53.8) | p < 0.001 | 65% reduction |
